Poliklinika Anova d.o.o.

Poliklinika Anova d.o.o. in Zagreb is conducting research aimed at the primary prevention of atherosclerotic cardiovascular disease, focusing on whether the novel therapy inclisiran can lower the incidence of major adverse cardiovascular events in high‑risk individuals.

• Testing a new lipid‑lowering agent in a primary‑prevention setting
• Measuring impact on cardiovascular death, myocardial infarction, stroke and urgent revascularisation
• Evaluating safety and tolerability in a real‑world patient population

The ongoing studies are double‑blind, placebo‑controlled trials designed to demonstrate the superiority of the investigational drug in reducing the composite 4P‑MACE endpoint, with a single investigator overseeing the work at this hospital‑clinic.